Protara Therapeutics, Inc. Increase (Decrease) in Operating Liabilities
Protara Therapeutics, Inc. (TARA) reported Increase (Decrease) in Operating Liabilities of $663.00 thousand for the 6-month period ending 2023-06-30, per its 10-Q filed 2023-08-03.
Discontinued › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInOperatingLiabilities · last filed 2023-08-03
- Protara Therapeutics, Inc. increase (decrease) in operating liabilities for the quarter ending 2023-06-30 was $331.00K, a 0.00% change year-over-year.
- Protara Therapeutics, Inc. increase (decrease) in operating liabilities for the quarter ending 2023-03-31 was $332.00K, a 0.00% change year-over-year.
- Protara Therapeutics, Inc. increase (decrease) in operating liabilities for the quarter ending 2022-12-31 was $332.00K, a 9.93% increase year-over-year.
- Protara Therapeutics, Inc. increase (decrease) in operating liabilities for the quarter ending 2022-09-30 was $332.00K, a 8.50% increase year-over-year.
- Protara Therapeutics, Inc. increase (decrease) in operating liabilities for fiscal 2022 was $1.33M, a 31.52% increase from fiscal 2021.
- Protara Therapeutics, Inc. increase (decrease) in operating liabilities for fiscal 2021 was $1.01M, a 1428.79% increase from fiscal 2020.
- Protara Therapeutics, Inc. increase (decrease) in operating liabilities for fiscal 2020 was $66.00K.
| Period end | Increase (Decrease) in Operating Liabilities 3 month | Increase (Decrease) in Operating Liabilities 3 month as first filed | Increase (Decrease) in Operating Liabilities 6 month | Increase (Decrease) in Operating Liabilities 9 month | Increase (Decrease) in Operating Liabilities 12 month |
|---|---|---|---|---|---|
| 2023-06-30 | $331.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-03 | $663.00K 10-Q · filed 2023-08-03 | $995.00K derived: sum of 3 quarters · filed 2023-08-03 | $1.33M derived: sum of 4 quarters · filed 2023-08-03 | |
| 2023-03-31 | $332.00K 10-Q · filed 2023-05-04 | $664.00K derived: sum of 2 quarters · filed 2023-05-04 | $996.00K derived: sum of 3 quarters · filed 2023-05-04 | $1.33M derived: sum of 4 quarters · filed 2023-08-03 | |
| 2022-12-31 | $332.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-08 | $664.00K derived: sum of 2 quarters · filed 2023-03-08 | $995.00K derived: sum of 3 quarters · filed 2023-08-03 | $1.33M 10-K · filed 2023-03-08 | |
| 2022-09-30 | $332.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-03 | $663.00K derived: sum of 2 quarters · filed 2023-08-03 | $995.00K 10-Q · filed 2022-11-03 | $1.30M derived: sum of 4 quarters · filed 2023-08-03 | |
| 2022-06-30 | $331.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-03 | $663.00K 10-Q · filed 2023-08-03 | $965.00K derived: sum of 3 quarters · filed 2023-08-03 | $1.27M derived: sum of 4 quarters · filed 2023-08-03 | |
| 2022-03-31 | $332.00K 10-Q · filed 2023-05-04 | $634.00K derived: sum of 2 quarters · filed 2023-05-04 | $940.00K derived: sum of 3 quarters · filed 2023-05-04 | $1.29M derived: sum of 4 quarters · filed 2023-05-04 | |
| 2021-12-31 | $302.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-08 | $608.00K derived: sum of 2 quarters · filed 2023-03-08 | $957.00K derived: sum of 3 quarters · filed 2023-03-08 | $1.01M 10-K · filed 2023-03-08 | |
| 2021-09-30 | $306.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-03 | $655.00K derived: sum of 2 quarters · filed 2022-11-03 | $707.00K 10-Q · filed 2022-11-03 | $712.00K derived: sum of 4 quarters · filed 2022-11-03 | |
| 2021-06-30 | $349.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-09 | $401.00K 10-Q · filed 2022-08-09 | $406.00K derived: sum of 3 quarters · filed 2022-08-09 | $428.00K derived: sum of 4 quarters · filed 2022-08-09 | |
| 2021-03-31 | $52.00K 10-Q · filed 2022-05-05 | $52.00 10-Q · filed 2021-05-06 | $57.00K derived: sum of 2 quarters · filed 2022-05-05 | $79.00K derived: sum of 3 quarters · filed 2022-05-05 | $118.00K derived: sum of 4 quarters · filed 2022-05-05 |
| 2020-12-31 | $5.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-09 | $27.00K derived: sum of 2 quarters · filed 2022-03-09 | $66.00K derived: sum of 3 quarters · filed 2022-03-09 | $66.00K 10-K · filed 2022-03-09 | |
| 2020-09-30 | $22.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-04 | $61.00K derived: sum of 2 quarters · filed 2021-11-04 | $61.00K 10-Q · filed 2021-11-04 | ||
| 2020-06-30 | $39.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-05 | $39.00K 10-Q · filed 2021-08-05 | |||
| 2020-03-31 | $0.00 10-Q · filed 2021-05-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Compass Therapeutics, Inc. (CMPX) | United States | $0.204B | -5.35 |
| Alpha Cognition Inc. (ACOG) | $0.185B | -6.77 | |
| Alector, Inc. (ALEC) | United States | $0.213B | -1.90 |
| Coherus Oncology, Inc. (CHRS) | United States | $0.182B | -1.63 |
| ANAVEX LIFE SCIENCES CORP. (AVXL) | United States | $0.218B | -18.37 |
| Protalix BioTherapeutics, Inc. (PLX) | $0.221B | 9.87 | |
| PRECISION BIOSCIENCES INC (DTIL) | United States | $0.175B | -3.95 |
| Voyager Therapeutics, Inc. (VYGR) | United States | $0.173B | -1.99 |
| Acumen Pharmaceuticals, Inc. (ABOS) | United States | $0.162B | -1.83 |
| Outlook Therapeutics, Inc. (OTLK) | United States | $0.162B | -4.90 |